Scholarlink

<p>In this study, furan-based crosslinked poly(methyl methacrylate) (DFA-PMMA) composites coated with carrageenan-kappa were synthesized to enhance solubility and cytotoxic efficacy against A549 lung cancer cells. FTIR analysis confirmed successful crosslinking through the appearance of amide C = O stretching at 1658&#xa0;cm⁻¹. XRD patterns revealed a shift towards amorphous structures with broadened peaks around 30°, indicating reduced crystallinity. Thermogravimetric analysis (TGA) demonstrated enhanced thermal stability, with T10% degradation temperatures increasing from 253&#xa0;°C (PMMA) to 278&#xa0;°C (DFA-PMMA5). Differential Scanning Calorimetry (DSC) results further showed a rise in glass transition temperature (Tg) from 105&#xa0;°C for PMMA to 121&#xa0;°C for DFA-PMMA5, indicating increased crosslinking density. Cytotoxicity assays revealed a significant reduction in IC50 values from 175&#xa0;µg/mL (PMMA) to 72&#xa0;µg/mL (DFA-PMMA5), and further down to 4.67&#xa0;µg/mL for carrageenan-coated DFA-PMMA5, highlighting improved anticancer activity. Solubility testing revealed enhancements by approximately 10-fold in HCl and 4-fold in pH 6.8 media. The developed composites offer promising potential as bioactive polymeric systems for targeted lung cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dissolution and lung cancer cells sensitivity enhancement using Furan-based crosslinked PMMA coated with carrageenan kappa

  • 期刊论文

  • 发表日期：

    2025年12月12日

查看全文
  • Bayan Alghamdi,
  • Nada Tashkandi,
  • Samaa Abdullah,
  • Samar Thiab,
  • Fatemah S. Basingab,
  • Nazeeha S. Alkayal

摘要

In this study, furan-based crosslinked poly(methyl methacrylate) (DFA-PMMA) composites coated with carrageenan-kappa were synthesized to enhance solubility and cytotoxic efficacy against A549 lung cancer cells. FTIR analysis confirmed successful crosslinking through the appearance of amide C = O stretching at 1658 cm⁻¹. XRD patterns revealed a shift towards amorphous structures with broadened peaks around 30°, indicating reduced crystallinity. Thermogravimetric analysis (TGA) demonstrated enhanced thermal stability, with T10% degradation temperatures increasing from 253 °C (PMMA) to 278 °C (DFA-PMMA5). Differential Scanning Calorimetry (DSC) results further showed a rise in glass transition temperature (Tg) from 105 °C for PMMA to 121 °C for DFA-PMMA5, indicating increased crosslinking density. Cytotoxicity assays revealed a significant reduction in IC50 values from 175 µg/mL (PMMA) to 72 µg/mL (DFA-PMMA5), and further down to 4.67 µg/mL for carrageenan-coated DFA-PMMA5, highlighting improved anticancer activity. Solubility testing revealed enhancements by approximately 10-fold in HCl and 4-fold in pH 6.8 media. The developed composites offer promising potential as bioactive polymeric systems for targeted lung cancer therapy.